LinkedIn Profile

Access Tenzing Group historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
private:tenzinggroup-2 2813376 Jun 3rd, 2019 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Jun 3rd, 2019 07:17PM Jun 3rd, 2019 07:17PM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Open Regulatory Affairs, Mobile Health, Mobile Medical Applications, Legislative Affairs Open P.O. Box 356 Santa Clara CA US 95052 Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Mar 23rd, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Mar 23rd, 2017 10:51AM Mar 23rd, 2017 10:51AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 17th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 16th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 15th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 14th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 13th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 12th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 11th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology
private:tenzinggroup-2 2813376 Feb 10th, 2018 12:00AM Tenzing Group, LLC 9 0.00 Open Hospital & Health Care Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Discounting future regulatory costs is extremely dangerous for start-up developers. By not preparing for the cost of 510(k) approval in addition to the added time for product deployment, these start-ups are ignoring a burden that could ultimately cost them their company. The Tenzing Group, LLC, can help these start-ups navigate the massive and confusing landscape that is the FDA. Using current regulations, our regulatory review will first analyze the mobile medical application's (MMA's) stance within the FDA and provide quality feedback on whether their product currently falls under FDA jurisdiction. Next, we will discuss potential FDA regulation, using draft guidance and other materials alluding to the FDA’s stance, which could bring the MMA into the guise of the FDA. Once we make our conclusions about regulation we then will inform the company about the costs associated with FDA compliance and approval and ways to mitigate those costs through implementing FDA mandated practices in the early stages of development. Finally, using data obtained through client interviews, we will offer best business practices and marketing strategies that will help alleviate the regulatory burden. This report will supply the start-up and any potential investors with the valuable information needed to prepare for the FDA, thus giving them a leg-up over their competitors and helping to create a sustainable and profitable business that will succeed despite regulation. Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.